Video-based automatic seizure detection in pharmacoresistant epilepsy: A prospective exploratory study
We are happy to share a prospective exploratory study conducted at Linköping University Hospital, evaluating the diagnostic yield and clinical utility of Nelli in patients with pharmacoresistant epilepsy. The study, published in Epilepsy and Behavior, was led by Fredrik K. Andersson and his team from Linköping University Hospital, where Nelli is used to provide crucial insights into the management and diagnosis of pharmacoresistant epilepsy.
The study is titled “Video-based automatic seizure detection in pharmacoresistant epilepsy: A prospective exploratory study” by Fredrik K. Andersson, Helena Gauffin, Hans Lindehammar, and Patrick Vigren.
- 20 adult patients with pharmacoresistant epilepsy included
- Participants were monitored at home using Nelli® for a median of 15.5 nights to capture nocturnal seizures
- Videos analyzed by a multidisciplinary team of clinical experts to validate Nelli classifications
Enhancing patient safety, refining diagnostics, and improving resource allocation in epilepsy care, Nelli
- Enabled diagnosis of 55% and epileptic seizures were identified in 45% participants
- PNES diagnosed in one participant
- 81.8% diagnostic yield for motor seizures
- Need for vEEG was obviated in 20%, a new diagnosis to 25%, treatment adjustments 25%, therapeutic interventions 30% participants
The study concluded that Nelli is useful method to evaluate patients with pharmacoresistant epilepsy and motor seizures (hyperkinetic, tonic, clonic, focal to bilateral tonic-clonic seizures); it may facilitate the diagnostic process in patients referred for long-term inpatient video-EEG evaluation and beneficially change anti-seizure treatments. Nelli provided accurate classification of motor seizures as epileptic, or non-epileptic, and may serve as a useful diagnostic tool to distinguish epileptic and non-epileptic episodic events with a motor component.
With its ability to classify epileptic and non-epileptic events accurately, Nelli offers a cost-effective and efficient alternative for diagnosing pharmacoresistant epilepsy in outpatient settings.
Dive deeper into the study: https://www.sciencedirect.com/science/article/pii/S1525505024005006